Criterios de Evaluación en Tumores Sólidos 1.1 (RECIST 1.1) en pacientes con Cáncer Primario y/o Metastásico o Enfermedad Metastásica Recurrente

Background: Radiological and imaging studies play an important role in the quantification of the tumor response to pharmacological treatment, radiotherapy or in combination. The RECIST 1.1 criteria allow classification of the clinical response in patients with tumors from diagnosis to outcome. The aim of the present study was to evaluate the clinical response to the treatment of chemotherapy and chemotherapy with radiotherapy in patients with primary and metastatic or recurrent cancer. Methodology; A retrospective and descriptive study in which a total of 143 cancer patient registries were divided into 2 groups: group 1 receiving chemotherapy treatment and group 2 receiving chemo and radiotherapy. Results: All patients reported neoplastic pathology; in group 1,the clinical response to the ninth month showed an increase in disease progression with 36.1%; group 2 presented a frequency of 26.5% in the progression of the disease. Conclusion: The RECIST 1.1 criteria are a good method of radiological evaluation of the clinical response to the applied therapy, monitoring the response to treatment is an integral function that increases the importance of the radiologist who is dedicated to the evaluation of cancer patients. In our study, it appears that the best treatment with the highest clinical response was combined with chemotherapy and radiotherapy.